ROAD TO THE CURE UPDATE JANUARY 2017

“...the biologics (drugs) capable of modifying and/or halting the brain diseases are prevented from entering the brain... ICBII’s SMART Molecules … making it the first company in the world to detect… and stop its expression…” This is an exciting time in the scientific community and in ICBI’s world. Scientists from around the world are recognizing the work ICBI has completed to date and are wanting to be a part of this unparalleled history as recognized in ICBI Engaging Dr. Serge Muyldermans as Scientific Advisor.

The San Diego biotech company, ICB International, Inc., (“ICBII”), appointed Dr. Serge Muyldermans, Professor of Immunology, Vrije Universiteit Brussel, to its Scientific Advisory Board. Dr. Muyldermans is a pioneer in the field of single-domain antibodies and their applications to immunological diseases such as Alzheimer’s and Parkinson’s. ICBI management is confident that Dr. Muylderman’s know-how, several decades’ hands-on experience with single-domain antibodies and his intellectual contributions to our ongoing neurosciences projects will speed up the market penetration of our drugs. Based in La Jolla, California, ICBII is a biomedicine company developing non-invasive diagnostics for early detection and disease altering therapies for neurodegenerative Alzheimer’s and Parkinson’s diseases. The Company has developed SMART (Specific Molecular Architecture for Recognition and Therapy) Molecules (SMs) technology that has been proven not only to efficiently cross the hitherto impermeable blood-brain barrier (BBB) but also detect pathogenic, aberrant proteins such as alpha-synuclein, Tau and LRRK2, and stops its gene expression in the central nervous system (CNS) of an animal model. Alzheimer’s and Parkinson’s diseases have become global epidemics with no relief in sight for more than 55 million individuals afflicted by the diseases. These and many other brain disorders are hidden behind the impermeable BBB and hence have escaped early detection and therapeutic correction/intervention. Not to speak of disease halting therapies, even today definite disease diagnosis is accomplished postmortem, though billions of dollars have been spent by big pharmaceutical companies, academic and governmental institutions to develop disease halting therapies for brain disorders. In spite of the best efforts by the global scientific and medical communities over the last several decades, the drugs developed so far only provide a short-term symptomatic relief without any impact on the disease progression.

The BBB is a formidable physiological barrier whose properties were discovered in the 1880s. This barrier is like a security gate that lets in materials such as sugars and amino acids the brain needs, while blocking or deflecting the many it does not. In particular, the biologics (drugs) capable of modifying and /or halting the brain diseases are prevented from entering the brain. ICBII’s SMART Molecules technology overcomes this problem, making it the first Company in the world to detect aberrant CNS proteins such as αα-synuclein, Tau & LRRK2, and stop their expression in an animal model. This technology is protected by two patents and several other patents that are under different stages of prosecution. The Company is talking with Angel investors, investment bankers and venture capitalists to raise the needed funds for scaling up the production of its CNS drugs, file IND (Investigational New Drug) applications with the US FDA and begin human clinical trials. In January 2016 we started reporting about the ICBI-Pharma Collaboration. Although it is still going forth, due to a reorganization at its headquarters, the US big pharmaceutical company could not conduct the experiment that was scheduled to be performed in September, 2016. The pharmaceutical company’s scientists then set up the date of December 14 to conduct the validation experiment. Unfortunately, from age-related factors, between September and December, several mice had died which delayed the experiment even further. ICBI and the pharmaceutical company scientists will regroup in January to strategize and set up a new target date to conduct the experiment. Besides the excitement of adding Dr. Serge Muyldermans to the ICBI team, we are pleased to report on the Therapeutic Efficacy of our Parkinson’s Drug (alpha-Synuclein-SMART Molecule).

With demonstrated therapeutic effect of our drug to halt the progression of Parkinson’s disease in animals, the year 2016 has been remarkably very successful for ICBI and its investors. We have now proven that the ICBII’s SMART molecules technology is not only capable of early detecting Parkinson’s but also stopping the disease progression in animals. The Company has accomplished all this with the fewest dollars in the history of medical sciences. Imagine, had we had access to the $5M back in 2012, TODAY we would have been conducting human clinical trials. Just imagine! We look forward to 2017 with great expectations. Our Immediate Plans are to take our drug to the patients. The following, in the months identified, needs to happen before starting clinical trials. All it takes is the funding. i) Drug needs to be cloned and manufactured   (9-12 months) ii) Submit an IND application with the USFDA for approval (3 months) iii) Conduct Phase-1 human trials (6-12 months). IMAGINE a world with no Parkinson’s or Alzheimer’s disease. Just Imagine.